NCT01592370 2025-10-22An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaBristol-Myers SquibbPhase 1/2 Completed320 enrolled 35 charts
NCT02304458 2023-10-17Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasNational Cancer Institute (NCI)Phase 1/2 Completed140 enrolled 23 charts
NCT01822509 2021-06-24Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNational Cancer Institute (NCI)Phase 1 Completed71 enrolled